Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Aug 19;368(9536):679-86.
doi: 10.1016/S0140-6736(06)69252-0.

Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis

Thomas A Gaziano  1 , Lionel H Opie, Milton C Weinstein
Affiliations
Review

Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis

Thomas A Gaziano et al. Lancet. .

Abstract

Background: Cardiovascular disease is the leading cause of death, with 80% of cases occurring in developing countries. We therefore aimed to establish whether use of evidence-based multidrug regimens for patients at high risk for cardiovascular disease would be cost-effective in low-income and middle-income countries.

Methods: We used a Markov model to do a cost-effectiveness analysis with two combination regimens. For primary prevention, we used aspirin, a calcium-channel blocker, an angiotensin-converting-enzyme inhibitor, and a statin, and assessed them in four groups with different thresholds of absolute risks for cardiovascular disease. For secondary prevention, we assessed the same combination of drugs in one group, but substituted a beta blocker for the calcium-channel blocker. To compare strategies, we report incremental cost-effectiveness ratios (ICER), in US dollars per quality-adjusted life-year (QALY).

Findings: We recorded that preventive strategies could result in a 2-year gain in life expectancy. Across six developing World Bank regions, primary prevention yielded ICERs of US746-890 dollars/QALY gained for patients with a 10-year absolute risk of cardiovascular disease greater than 25%, and 1039-1221 dollars/QALY gained for those with an absolute risk greater than 5%. ICERs for secondary prevention ranged from 306 dollars/QALY to 388 dollars/QALY gained.

Interpretation: Regimens of aspirin, two blood-pressure drugs, and a statin could halve the risk of death from cardiovascular disease in high-risk patients. This approach is cost-effective according to WHO recommendations, and is robust across several estimates of drug efficacy and of treatment cost. Developing countries should encourage the use of these inexpensive drugs that are currently available for both primary and secondary prevention.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

We declare that we have no conflict of interest.

Figures

Figure
Figure
Lifetime costs and QALYs of strategies assessed in six World Bank regions
See this image and copyright information in PMC

Comment in

References

    1. Mathers CD, Lopez A, Stein C, et al. Working paper 18. Bethesda, MD: Disease Control Priorities Project; 2005. Deaths and disease burden by cause: global burden of disease estimates for 2001 by World Bank Country Groups.
    1. Fuster V, Voûte J. MDGs: chronic diseases are not on the agenda. Lancet. 2005;366:1512–14. - PubMed
    1. Horton R. The neglected epidemic of chronic disease. Lancet. 2005;366:1514. - PubMed
    1. World Bank. World development indicators. Washington, DC: World Bank; 2002.
    1. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80% BMJ. 2003;326:1419. - PMC - PubMed

Publication types

MeSH terms

Substances